IOVA
IOVANCE BIOTHERAPEUTICS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 10 ▲ Iovance Biotherapeutics received marketing authorization from the Au…
- Jun 19 Activist stake: Iovance Biotherapeutics Reports Inducement Grants under NA…
- Jul 16 Iovance Biotherapeutics, Inc. v. Federal Insurance Company
- Aug 6 ▲ Iovance reported record Q2 2026 revenue of ~$99.3M, a 66% YoY increa…
- Aug 21 Activist stake: Iovance Biotherapeutics Reports Inducement Grants under NA…
- Sep 29 ▲ Iovance Biotherapeutics raised its full year 2026 total revenue guid…
- Sep 30 ▲ 3 funds open new positions (13F)
- Sep 30 ▲ Short interest falls 25.6% to 64.83M
- Oct 28 FDA: Iovance Biotherapeutics to Host Webcast on Positive Data f…
- Oct 28 ▲ Iovance Biotherapeutics announced positive results from the IOV-LUN-…
- Oct 29 ▲ Iovance reported updated Phase 2 IOV-LUN-202 results showing a 24.6%…
- Nov 5 ▲ Iovance Biotherapeutics reported record Q3 2026 revenue of ~$122M, u…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Mar 9. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q3 2026: 40 added (3 new), 21 trimmed or exited. Largest new: Arrowstreet Capital, Limited Partnership $16.6M.
- AnalystsBULLISH
13 of 16 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +10.6% to 65.19M shares. 4.2 days to cover, ≈14.1% of shares.
- TrendDOWNTREND
33% below its 50-day average.
- SocialQUIET
Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | ADD | $37.8M |
| Invesco Ltd. | ADD | $34.5M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $30.8M |
| HRT FINANCIAL LP | TRIM | $26.3M |
| FMR LLC | ADD | $25.3M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | NEW | $16.6M |
| MARSHALL WACE, LLP | DOUBLED | $13.7M |
| AMERICAN CENTURY COMPANIES INC | ADD | $12.7M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
16 analystsPrice is below the lowest target. Median implies +105%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | Barclays MAINTAIN | Overweight |
| Nov 6, 2026 | Citizens MAINTAIN | Market Outperform |
| Nov 3, 2026 | UBS MAINTAIN | Neutral |
| Oct 13, 2026 | Barclays MAINTAIN | Overweight |
| Oct 8, 2026 | Baird MAINTAIN | Neutral |
| Sep 30, 2026 | Wells Fargo MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Vogt Frederick G Interim CEO & General Counsel Nov 11, 2026 | EXERCISE | $1.5M |
Vogt Frederick G Interim CEO & General Counsel Nov 11, 2026 | TAX W/H | $1.5M |
Kirby Daniel Gordon Chief Commercial Officer Nov 10, 2026 | EXERCISE | 10,000 sh |
Kirby Daniel Gordon Chief Commercial Officer Nov 10, 2026 | TAX W/H | $31.8K |
Roche Corleen M. Chief Financial Officer Nov 6, 2026 | TAX W/H | $42.7K |
Roche Corleen M. Chief Financial Officer Nov 6, 2026 | EXERCISE | 12,500 sh |
Berkowitz Noah Chief Medical Officer Sep 30, 2026 | AWARD | 135,000 sh |
Berkowitz Noah Chief Medical Officer Sep 30, 2026 | AWARD | 180,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | -$0.04 | -$0.08–-$0.02 | +49.7% | $133.9M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
16 filings · 5 press releases · 5 bullish · 1 bearish · 10 neutral- NEUTRAL SC 13GNov 10, 2026
State Street Corp disclosed a 4.8% passive stake in Iovance Biotherapeutics as of September 30…
This filing confirms State Street's continued passive ownership at a stable level. No change in investment thesis; monitor for any future 13D conversion or material stake changes.
- NEUTRAL 8-KNov 5, 2026
Iovance Biotherapeutics filed an 8-K to update its corporate presentation, which includes a raised…
Monitor upcoming sBLA submission for lifileucel in 2L mNSCLC in 2027 and the OPTILISM Phase 3 trial initiation, as NSCLC represents a 10x larger opportunity than the current melanoma market. The…
- BULLISH 8-KNov 5, 2026
Iovance Biotherapeutics reported record Q3 2026 revenue of ~$122M, up ~80% YoY, with gross margin…
Revenue growth and margin expansion are accelerating, with FY26 guidance maintained. Key catalysts ahead include sBLA submission for lifileucel in mNSCLC in 2027 and potential UK/Switzerland…
- NEUTRAL INST-CLUSTERNov 3, 2026
Five asset managers increased their IOVA positions in Q3 2026, with Pictet Asset Management and…
The buying is concentrated among small-to-mid-size asset managers, not mega-passive funds, which adds conviction. However, the dollar amounts are immaterial relative to market cap, and the 45-day…
All IOVA filing & press-release reports (21)
- SC 13G reportNov 10, 2026
- 8-K reportNov 5, 2026
- 8-K reportNov 5, 2026
- INST-CLUSTER reportNov 3, 2026
- 8-K reportOct 29, 2026
- PRESS-RELEASE reportOct 28, 2026
- 8-K reportOct 5, 2026
- 3 reportOct 2, 2026
- 8-K reportSep 29, 2026
- PRESS-RELEASE reportAug 21, 2026
- 8-K reportAug 6, 2026
- 8-K reportAug 6, 2026
- COURT-RULING reportJul 16, 2026
- 8-K reportJul 2, 2026
- PRESS-RELEASE reportJun 19, 2026
- S-3ASR reportJun 18, 2026
- 8-K reportJun 10, 2026
- PRESS-RELEASE reportMay 22, 2026
- DEFA14A reportApr 28, 2026
- PRESS-RELEASE reportApr 27, 2026
- PRESS-RELEASE reportApr 17, 2026